Kura Oncology, Inc. (KURA) financial statements (2021 and earlier)

Company profile

Business Address 3033 SCIENCE PARK ROAD, SUITE 220
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments23717993688600
Cash and cash equivalents261611101500
Short-term investments211163825870  
Receivables00000  
Prepaid expense      0
Other undisclosed current assets32111  
Total current assets:24018195698700
Noncurrent Assets
Property, plant and equipment0(0)000  
Other noncurrent assets21110  
Other undisclosed noncurrent assets 0  0  
Total noncurrent assets:21110  
TOTAL ASSETS:24218296708700
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:151385400
Accounts payable4411100
Accrued liabilities1112 00
Employee-related liabilities43221  
Interest and dividends payable     0 
Other undisclosed accounts payable and accrued liabilities764 2  
Debt0 2    
Derivative instruments and hedges, liabilities    0  
Due to related parties     0 
Other undisclosed current liabilities 0011  
Total current liabilities:1614105500
Noncurrent Liabilities
Long-term debt and lease obligation7867   
Long-term debt, excluding current maturities7867   
Liabilities, other than long-term debt00000  
Other liabilities00000  
Total noncurrent liabilities:88670  
Other undisclosed liabilities     (0)0
Total liabilities:23211613500
Stockholders' equity
Stockholders' equity attributable to parent, including:219161805782(0)(0)
Common stock0000000
Additional paid in capital43131116911110800
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)  
Accumulated deficit(213)(150)(89)(54)(26)  
Other undisclosed stockholders' equity attributable to parent     (0)(0)
Total stockholders' equity:219161805782(0)(0)
TOTAL LIABILITIES AND EQUITY:24218296708700

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(67)(63)(36)(28)(24)(0)(0)
Operating loss:(67)(63)(36)(28)(24)(0)(0)
Nonoperating income42111  
Investment income, nonoperating  100  
Interest and debt expense(1)(0)(1) (0)(0)(0)
Net loss:(64)(61)(36)(28)(23)(0)(0)
Other undisclosed net income attributable to parent101 0  
Net loss available to common stockholders, diluted:(63)(60)(35)(28)(23)(0)(0)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(64)(61)(36)(28)(23)(0)(0)
Other comprehensive income (loss)0(0)     
Comprehensive loss:(63)(61)(36)(28)(23)(0)(0)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1010(0)  
Comprehensive loss, net of tax, attributable to parent:(63)(61)(35)(27)(23)(0)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: